ICH: sudden severe headache, vomiting, reduced consciousness, rapidly progressive deficit
Hypertensive encephalopathy: headache, confusion, visual disturbance, seizures with severely raised BP
Look for hypertensive end-organ failure (cardiac, renal, aortic dissection)
Investigations
Urgent non-contrast CT head to distinguish ischaemic stroke from ICH (Β± CT angiography per stroke pathway)
Confirm BP with two consecutive readings above threshold before starting IV treatment; monitor continuously or frequently once treating
GCS, heart rate, ECG, renal function; assess for end-organ failure
Check labetalol contraindications before use (see treatment); discuss starting IV BP control with a senior/consultant
Treatment
ICH β when to treat: within 6h of onset (and up to 7 days) if SBP >150 mmHg; target SBP <140 mmHg as soon as possible (within 1h of the CT result). Guideline update: consider rapid lowering if SBP 150β220 within 6h, or case-by-case if >6h or SBP >220; aim for β€140 mmHg within 1h of starting treatment, avoiding a fall of >60 mmHg in the first hour. Afterwards keep SBP 140β180 mmHg for the next 7 days
ICH β do NOT lower BP rapidly if: GCS below 5β6; haematoma very large with death expected; structural cause identified (tumour, AVM, aneurysm); immediate surgery to evacuate the haematoma planned
Ischaemic stroke β thrombolysis candidates: treat if SBP >180 or DBP >105 mmHg before alteplase and for 24h after the bolus; target SBP <180 or DBP <110 mmHg as soon as possible (literature: AHA/ASA uses <185/110 before and <180/105 for 24h after)
Ischaemic stroke β not thrombolysed: do NOT treat high BP for the first 2 weeks unless there is evidence of end-organ failure, or SBP >220 (or DBP >120) mmHg on two consecutive readings
Hypertensive encephalopathy/emergency: lower slowly β reduce mean arterial pressure by 10% per hour and by no more than 25% of the original value; MAP = diastolic + β (systolic β diastolic); target SBP <140 mmHg
Step 1 β labetalol bolus:Labetalol 10mg IV bolus; recheck BP at 5 and 10 min (peak effect 5β10 min); if SBP still above target at 10 min give a second bolus of 20mg IV. If at target: BP and HR every 30 min for 6h
Step 2 β labetalol infusion (SBP still above target after boluses): undiluted 5 mg/mL (100mg/20mL ampoules; 3 ampoules = 300mg/60mL in a syringe pump). Start 5 mL/h (25 mg/h); increase or decrease by 1 mL/h every 15β30 min. Measure SBP and HR at 5, 10, 20 and 30 min after starting or any rate change, then every 30 min for 6h. If good response continue for 24h, then switch to enteral antihypertensives. Flush with 0.9% saline; use a large-bore cannula (thrombophlebitis)
Labetalol contraindications: hypersensitivity; bradycardia (<45β50 bpm); hypotension; history of wheeze/asthma; metabolic acidosis; cardiogenic shock; uncontrolled heart failure; severe peripheral circulatory disturbance; sick sinus syndrome; Prinzmetal's angina; second/third-degree heart block
Adjusting any infusion (labetalol or GTN): CONTINUE current rate if SBP 134β140 (ICH/hypertensive emergency) or 161β180 (thrombolysis); TAPER if SBP 120β130 (ICH/hypertensive emergency) or 140β160 (thrombolysis); STOP if SBP <120 (ICH/hypertensive emergency) or <140 (thrombolysis)
Step 3 β GTN infusion (labetalol contraindicated or ineffective; or SBP above threshold on two readings despite maximum labetalol, or HR <50/min): stop labetalol and use GTN 50mg/50mL (1 mg/mL) undiluted via syringe pump, starting at 0.6 mL/h; titrate up/down by 1 mL/h every 15β30 min to a maximum of 12 mL/h; monitor BP continuously. If SBP not at target after 30 min at 12 mL/h, contact a senior doctor to consider other options. Side effects: headache, dizziness, flushing, hypotension, tachycardia; caution in severe liver/renal failure; nitrate tolerance may develop within 24h
Alternative (literature, if labetalol contraindicated/unsuitable):Nicardipine 5 mg/h IV, increase by 2.5 mg/h every 5β15 min to a maximum of 15 mg/h β check local availability
Longer term: establish the enteral route as soon as possible; restart regular pre-admission antihypertensives and adjust the dose or add an agent to reach the target SBP; start oral antihypertensives as soon as practical